News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lumenis Ltd. (LUME) To Ring The NASDAQ Stock Market Closing Bell On June 19, 2014



6/19/2014 12:31:55 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

YOKNEAM, ISRAEL--(Marketwired - June 19, 2014) - Lumenis Ltd. (NASDAQ: LMNS), the world largest medical energy-based solutions company for surgical, ophthalmology and aesthetic applications, will be ringing the closing bell at the NASDAQ MarketSite in Times Square, New York, NY on Thursday, June 19, 2014, at 4:00 p.m. ET.

Chief Executive Officer Tzipi Ozer-Armon and the Lumenis management team will participate in the bell ringing ceremony from 3:45 to 4:00 p.m. ET, to commemorate the listing of Lumenis on the NASDAQ Global Select Market on February 27, 2014 under the symbol "LMNS". A live webcast will be available at https://new.livestream.com/nasdaq/live.

"2014 thus far has been a pivotal year for Lumenis," said Ms. Ozer-Armon. "Following our successful IPO in February, the Company has launched an unprecedented number of new products in 2014, including the Pulse 120H, the most powerful holmium laser for urological procedures, two additions to our gold standard LightSheer laser hair removal platform and also rolled out globally the Array. The IPO was an important milestone for us, and as we are commemorating it today by ringing the NASDAQ closing bell, we are excited about our future growth opportunities."

About Lumenis
Lumenis (NASDAQ: LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare.

For more information visit: www.lumenis.com

Forward-Looking Statements

Information provided in this release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and Lumenis undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.


For further information:
Jeff Jacomowitz
Lazar Partners Ltd.
(212) 867-1762
jrjacomowitz@lazarpartners.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES